Pyrotinib

Generic Name: Pyrotinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₃₁ClN_₆O_₃

CAS Number: 1269662-73-8

Unique Ingredient Identifier: CJN36EQM0H

Background: Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib

First Posted Date: 2022-12-02

Last Posted Date: 2024-07-05

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 65

Registration Number: NCT05635487

Locations: 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

First Posted Date: 2022-10-17

Last Posted Date: 2024-08-06

Lead Sponsor: Fudan University

Target Recruit Count: 716

Registration Number: NCT05582499

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab
Drug: pyrotinib
Drug: Dalpiciclib
Drug: fulvestrant

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT05577923

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

Not yet recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Pyrotinib

First Posted Date: 2022-09-30

Last Posted Date: 2022-09-30

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05561686

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3

Conditions: HER2+ Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pyrotinib
Drug: Anti-PD-1 monoclonal antibody
Drug: CDK4/6 inhibitor
Drug: Pertuzumab
Drug: Capecitabine
Drug: Nab paclitaxel
Drug: AI
Drug: T-DM1
Drug: Everolimus

First Posted Date: 2022-06-23

Last Posted Date: 2022-06-23

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 120

Registration Number: NCT05429684

Locations: 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳
Jin Yang, Xi'an, Shaanxi, China

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Pyrotinib

First Posted Date: 2022-06-23

Last Posted Date: 2022-06-23

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 209

Registration Number: NCT05429294

Locations: 🇨🇳
Jin Yang, Xi'an, Shaanxi, China

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: pyrotinib

First Posted Date: 2022-02-24

Last Posted Date: 2022-02-24

Lead Sponsor: Fujian Medical University Union Hospital

Target Recruit Count: 60

Registration Number: NCT05255523

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2

Conditions: Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Camrelizumab
Drug: Pyrotinib
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: S-1

First Posted Date: 2021-11-08

Last Posted Date: 2021-11-08

Lead Sponsor: Fudan University

Target Recruit Count: 65

Registration Number: NCT05111444

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）

Conditions: Salivary Gland Neoplasms

Interventions: Drug: Pyrotinib
Drug: Bicalutamide
Drug: Leuprorelin

First Posted Date: 2021-10-21

Last Posted Date: 2021-10-21

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 182

Registration Number: NCT05087706

Locations: 🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Phase 2

Recruiting

Conditions: Estrogen Receptor-positive Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Palbociclib
Drug: trastuzumab
Drug: pyrotinib
Drug: fulvestrant

First Posted Date: 2021-10-13

Last Posted Date: 2021-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 37

Registration Number: NCT05076695

Locations: 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy